Imidazotriazine derivatives acting as interleukin-17 (IL-17) modulators have been described in a UCB SA patent and are reported to be potentially useful for the treatment of inflammatory disorders and autoimmune diseases.

A Sanofi SA patent describes imidazopyridine compounds acting as mitogen-activated protein kinase 7 (MAPK7; ERK5) inhibitors and reported to be useful for the treatment of cancer.

Ildong Pharmaceutical Co. Ltd. have synthesized heteroaryl derivative compounds acting as anoctamin-6 (ANO6; TMEM16F) blockers.

Genescience Pharmaceuticals Co. Ltd. has described cannabinoid CB2 receptor agonists reported to be useful for the treatment of arthritis, systemic lupus erythematosus, inflammatory bowel disease, allergic contact dermatitis, colitis, autoimmune diseases and pain.

Insilico Medicine IP Ltd. has divulged E3 ubiquitin-protein ligase CBL-B (CBLB) inhibitors reported to be useful for the treatment of cancer.

Shanghai Sinotau Biotech Co. Ltd. has identified tyrosine-protein phosphatase non-receptor type 13 (PTPN13; FAP-1; PTP-1E) inhibitors reported to be useful for the treatment of cancer.

Betta Pharmaceuticals Co. Ltd. has synthesized EGFR (HER1; erbB1) mutant inhibitors reported to be useful for the treatment of cancer.

Shanghai Boyue Biotechnology Co. Ltd. has disclosed hepatocyte growth factor receptor (HGFR; MET) and tyrosine-protein kinase receptor UFO (AXL) inhibitors reported to be useful for the treatment of cancer.

Shaanxi Synthetic Pharmaceutical Co. Ltd. has described compounds reported to be useful for the treatment of coronavirus acute respiratory syndrome.

Nextgen Bioscience Co. Ltd. has divulged ectonucleotide pyrophosphatase/phosphodiesterase family member 2 (ENPP2; autotaxin) inhibitors reported to be useful for the treatment of cancer, fibrosis, cardiovascular, inflammatory, respiratory, metabolic, eye and renal disorders, among others.<